{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapeutic+cytotoxic+T+lymphocytes", "query": { "intervention": "therapeutic cytotoxic T lymphocytes" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 259, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapeutic+cytotoxic+T+lymphocytes&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T13:15:45.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05377528", "title": "Study of AGEN1571 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "AGEN1571", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-07-19", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05377528" }, { "nct_id": "NCT05350501", "title": "EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "EO2040", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enterome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-03-01", "completion_date": "2024-01-23", "has_results": true, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05350501" }, { "nct_id": "NCT02500797", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bone Sarcoma", "Locally Advanced Dedifferentiated Liposarcoma", "Locally Advanced Gastrointestinal Stromal Tumor", "Locally Advanced Soft Tissue Sarcoma", "Metastatic Bone Sarcoma", "Metastatic Liposarcoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Metastatic Unresectable Sarcoma", "Pleomorphic Liposarcoma", "Stage III Bone Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Bone Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Bone Sarcoma AJCC v7", "Stage IVB Bone Sarcoma AJCC v7", "Unresectable Bone Sarcoma", "Unresectable Dedifferentiated Liposarcoma", "Unresectable Liposarcoma", "Unresectable Malignant Gastrointestinal Stromal Tumor", "Unresectable Soft Tissue Sarcoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2015-08-13", "completion_date": "2023-04-01", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 651, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500797" }, { "nct_id": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2019-05-13", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 580, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866382" }, { "nct_id": "NCT05341349", "title": "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Melanoma of Unknown Primary", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Ocular Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Tumor Treating Fields Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 1, "start_date": "2022-10-13", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05341349" }, { "nct_id": "NCT04396860", "title": "Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gliosarcoma", "MGMT-Unmethylated Glioblastoma" ], "interventions": [ { "name": "Contrast-enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "NovoTTF-100A Device", "type": "DEVICE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DEVICE", "OTHER", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2020-09-01", "completion_date": "2025-12-23", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 285, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Auburn", "state": "California" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04396860" }, { "nct_id": "NCT02453620", "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "Invasive Breast Carcinoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Blood Sample", "type": "OTHER" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2016-02-12", "completion_date": "2027-09-11", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 5, "location_summary": "Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453620" }, { "nct_id": "NCT05101213", "title": "Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenovirus Infection", "BK Virus Infection", "Cytomegaloviral Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "JC Virus Infection", "Malignant Solid Neoplasm", "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Virus-specific Cytotoxic T-lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-01-06", "completion_date": "2026-08-03", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05101213" }, { "nct_id": "NCT02506153", "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Non-Cutaneous Melanoma", "Non-Cutaneous Melanoma", "Recurrent Cutaneous Melanoma", "Recurrent Mucosal Melanoma", "Recurrent Non-Cutaneous Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1301, "start_date": "2015-11-10", "completion_date": "2027-01-23", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 552, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02506153" }, { "nct_id": "NCT05572970", "title": "Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "Balstilimab", "type": "DRUG" }, { "name": "Zalifrelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-02T13:15:45.072Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Newport Beach, California + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05572970" } ] }